ICON contributes to major European research study that aims to improve treatment for traumatic brain injury
Recommendations from the longitudinal observational research study will be presented today at the European Parliament
Dublin, Ireland, 7 November 2017 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has contributed to a complex pan-European traumatic brain injury (TBI) research study involving over 4,500 patients in 65 sites in 20 European countries. ICON provided site management and source data verification (SDV) services to the study, which was supported by the European Union and led by Professor Andrew Maas from the University Hospital Antwerp (Belgium) and Professor David Menon from the University of Cambridge (UK). ICON’s Dr. Valérie Legrand, VP Project Management and a recognised expert in CNS, also provided clinical expertise as a member of the project’s Management Committee. The Lancet Neurology Commission on TBI is being launched at the European Parliament today and will set out clinical and research priorities and recommendations to address the varied challenges in TBI.
Almac Group Announces Acquisition of BioClin Laboratories
Significant global expansion of existing analytical services
Craigavon, N.I., 01 November 2017 – Almac Group, the global contract development and manufacturing organisation, today announced the acquisition of 100% shares of BioClin Laboratories, an independent and privately owned organisation based in Athlone, Ireland.
Established in 2002 and located in Garrycastle, just two hours away from Almac Group’s Headquarters in Northern Ireland, BioClin is internationally recognised for providing expert analytical services including cGMP pharmaceutical and biopharmaceutical analysis, GMP microbiology testing and GLP bioanalysis. The company also boasts Ireland’s leading GLP certified (INAB), cGMP certified (HPRA) and FDA registered contract laboratory.
ICON and the International Consortium for Health Outcomes Measurement unveil the world’s first global patient outcomes benchmarking platform
Dublin, Ireland, 27 October 2017 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, and the International Consortium for Health Outcomes Measurement (ICHOM), a non-profit organization with the mission of driving value based health care, shared the findings of a global patient outcomes benchmarking platform at this week’s ICHOM’s annual conference in Washington DC. The platform aims to catalyse physician driven learning and improvement of the outcomes that matter most to patients.
ICON and ICHOM first partnered to advance value-based healthcare through the launch of a global healthcare outcomes benchmarking pilot program called GLOBE in March 2016.
PA Trade Mission visit to the McHale headquarters, just outside Ballinrobe, County Mayo.
#IABCN member, Joe Burke (2nd to left) with 2 Mayo County Council Economic Development Reps and (3rd from left) Paul McHale, Sales Manager; (center) Gene Barr, President & CEO of PA Chamber of Business and Industry; (2nd from right) Padraic McHale, Co-Owner and Founder.
McHale employs 250+, with 25% of their workforce is dedicated to R&D.
Almac Pod™ – Changing the Global Dynamics of Temperature Controlled Shipping Solutions
Introducing a new product to the US clinical trial supply marketplace
|Craigavon, N.I., UK, 16 October 2017 – Almac Group, the global contract development and manufacturing organisation, has recognised the need for a change in dynamics of temperature controlled shipping with the launch of its new Almac Pod™ service solution in the United States.
Understanding the cost, logistical and compliance challenges posed by this changing environment, the Almac Pod was originally released in Europe and serves as a first-to-market service solution. The innovative solution incorporates the efficiencies of the Almac-approved, global courier network and advanced phase change material technology (PCM) to create a temperature-controlled shipping service solution that eases the burden for its global clinical supply customers.